Aerie Pharmaceuticals (Aerie Pharmaceuticals) GF Score : 36/100 (As of May. 06, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals GF Score?

Aerie Pharmaceuticals has the GF Score of 36, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 3/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 10/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Aerie Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Aerie Pharmaceuticals's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aerie Pharmaceuticals's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's GF Score falls into.

Aerie Pharmaceuticals (NAS:AERI) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Aerie Pharmaceuticals GF Score Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703

Website

https://www.aeriepharma.com

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Executives

Peter Frederick Lang	officer: Chief Financial Officer	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan	director, officer: Chief Executive Officer	C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese	officer: Vice President of Finance	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley	officer: CHRO & VP, Corp Services	15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten	officer: Interim CFO	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski	officer: Chief Scientific Officer	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell	director	2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle	director	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander	officer: Chief R&D Officer	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino	officer: Chief Financial Officer
Vicente Jr Anido	director, officer: Chief Executive Officer	1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro	officer: President and COO	15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618